Loading…
← CockpitCompetitor Analysis › PSNL Personalis, Inc.Open in the cockpit ↗

Personalis, Inc.PSNLCompetitor analysis, valuation and peers

United States · USD·Health Care›Medical/Nursing Services

Genomics company providing advanced tumor and immune profiling tests to guide cancer treatment and monitor recurrence.

Momentum leader 90
Mkt cap
$1.62B
US dollars, full cap
Free float
67%
of shares outstanding
$/day
$35.9M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-185.5 pp
WACC 16.8%
Hurdle
n/a
no reverse DCF
Next earnings
99 days
25 Feb 2027
Close · USD$14.98
1D+1.2%
1W-6.1%
1M-6.0%
3M-11.3%
6M+88.4%
YTD+88.2%
1Y+100.3%
ATR %2.3%
Beta2.20
52w lowhigh20.7% off high

What Personalis does

Genomics company providing advanced tumor and immune profiling tests to guide cancer treatment and monitor recurrence.

Has long been paid mainly by drug developers for sequencing and tumour analysis in their trials, with a large share from one customer, Moderna. The NeXT Personal blood test, which looks for traces of cancer left after treatment, is the growth bet; its sales to clinicians depend on payers agreeing to cover it.

Products and services

  • NeXT Personal (minimal residual disease test)
  • Tumor profiling/immune-oncology testing
  • Pharma biomarker research services

Customers

  • Oncologists
  • Pharmaceutical/biotech companies (biomarker resear

Where it sits in the supply chain

  • Diagnostics
  • Cancer genomics
  • Comprehensive tumor/immune profiling…

What could go right

  • Minimal residual disease testing adoption growth
  • Pharma biomarker/companion diagnostic demand

What could go wrong

  • Reimbursement/payer coverage uncertainty
  • Cash burn/path-to-profitability risk

Moat: narrow (IP / patents, data). Proprietary highly-sensitive minimal-residual-disease test differentiates from broader liquid-biopsy competitors.

Headquarters: Fremont, California · Founded: 2011 · Employees: 260

Named competitors

Personalis at a glance

Size Personalis (PSNL) is a United States Health Care company (Medical/Nursing Services) with a market value of $1.62B, the 1908th largest of 3,085 United States companies the cockpit tracks. Shares closed at $14.98 on 18 Nov 2026.

Performance Over six months the shares gained 88.4%, against +17.1% for the median peer and -2.2% for the United States market (cap-weighted) — 3rd highest of 21 in its peer set.

Growth Revenue grew 16.9% over the last twelve months (peer median +7.9%); the operating margin is -156.7% (peer median 3.2%).

Valuation It trades at 18.2× enterprise value to sales against a peer median of 2.0× (most expensive of 21).

Capital Return on invested capital runs 185.5 points below its cost of capital (16.8% WACC).

Short interest Short interest is 6.2% of the free float (30 Oct 2026).

Next results Next results expected around 25 Feb 2027 (exchange calendar; dates can move).

Relative performance

10015020021 May 202621 Aug 202618 Nov 2026PSNL 182Peer median 116
Six months, rebased to 100: Personalis against the median of its 20 peers (local-currency closes).

Personalis financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$80.8M$69.6M$84.6M$73.5M$65.0M
Revenue growth—-18%+15%+13%—
Gross profit$13.5M$15.8M$26.8M$18.2M$13.3M
EBITDA-$117M-$78.0M-$57.3M-$85.0M-$103M
Net income-$119M-$81.3M-$81.3M-$108M-$113M
Free cash flow-$108M-$79.5M-$46.8M-$67.2M-$120M
Capital expenditure$10.1M$4.50M$1.60M$10.9M$49.9M
Total debt$37.2M$40.8M$44.4M$49.0M$49.0M

Quarterly statements and history in the cockpit →

Personalis competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+50%0%+20%SNDAAMBEAVIJAYAWGS300244AGLEMEISTDOC4544USPHAGARWALEYE1833LMRINEOCLARIAZTADIAPNTGOPKPSNL6-month return →1-month return →
Up and to the right = strong over both horizons. Personalis is the large dot.

Fundamentals: revenue growth against valuation

0%+20%+40%0×5×10×15×SNDAAMBEAVIJAYAWGS300244AGLEMEISTDOCUSPH603882AGARWALEYE1833AZTADIAPNTGOPKPSNLRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Personalis is the large dot.

Personalis competitors and peer comparison

Head to head with its named competitors (PSNL vs GH vs NTRA)
CompanyMarket cap6M returnRevenue growthOp. marginEV / SalesReq g
Personalis PSNL$1.62B+88%+17%-157%18.2×n/a
Guardant Health GH$19.6B+26%+42%-39%15.9×n/a
Natera NTRA$42.0B+41%+37%-9%14.1×n/a

How Personalis compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Personalis against its 20 peers (data as of 18 Nov 2026)
MeasurePSNLPeer medianRank in peer set
1-month return-6.0%+1.3%7th lowest of 21
6-month return+88.4%+17.1%3rd highest of 21
Distance from 52-week high-20.7%-24.1%10th highest of 21
Revenue growth (TTM)+16.9%+7.9%6th highest of 21
Operating margin-156.7%3.2%lowest of 21
EV / Sales18.2×2.0×most expensive of 21
ROIC minus cost of capital-185.5 pp-4.4 pplowest of 20

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Personalis PSNLUnited States$1.62B+88%+17%-157%18.2×n/an/a
Sonida Senior Living SNDAUnited States$1.59B-11%+70%-8%4.8×n/an/a
Ambea AMBEA.STSweden$1.59B+28%+11%9%1.7×1.1%+7.7%
Vijaya Diagnostic Centre VIJAYA.NSIndia$1.69B+18%+24%32%17.5×40.4%+16.7%
GeneDx WGSUnited States$1.56B+16%+15%-14%3.5×n/an/a
Dian Diagnostics 300244.SZChina$1.70B+1%-5%9%1.4×0.3%-1.1%
agilon health AGLUnited States$1.52B+12%+2%-2%0.2×n/an/a
Emeis EMEIS.PAFrance$1.78B-33%+4%3%1.6×21.2%+8.5%
Teladoc Health TDOCUnited States$1.47B+24%-2%-5%0.7×-6.4%+18.3%
H.U.Group 4544.TJapan$1.44B+24%+1%3%1.0×9.7%+2.1%
U.S. Physical Therapy USPHUnited States$1.42B+53%+10%10%2.6×18.8%+13.0%
Guangzhou Kingmed Diagnostics 603882.SSChina$1.86B+5%-3%7%1.9×5.4%-6.1%
Dr. Agarwal's Health Care AGARWALEYE.NSIndia$1.86B+20%+26%15%7.8×43.0%+26.9%
Ping An Healthcare and Technology 1833.HKHong Kong$1.36B-47%+8%3%0.4×3.5%-5.1%
Lumexa Imaging LMRIUnited States$1.35B+89%+8%2%2.1×n/an/a
NeoGenomics NEOUnited States$1.98B+72%+11%-6%2.9×n/an/a
Clariane CLARI.PAFrance$1.32B-20%+1%6%1.6×6.8%+6.5%
Azenta AZTAUnited States$2.03B+162%+5%-2%2.8×38.0%+3.9%
Diagnostyka DIA.WAPoland$1.28B-6%+19%15%2.5×7.3%+18.9%
Pennant PNTGUnited States$1.26B+1%+39%6%1.5×20.7%+19.4%
OPKO Health OPKUnited States$1.25B+37%-22%-29%2.8×n/an/a

Questions

Who are Personalis's main competitors?
Named competitors: Guardant Health (GH), Natera (NTRA), Exact Sciences (private or unlisted). The cockpit's measured peer set (industry) also includes Sonida Senior Living (SNDA), Ambea (AMBEA.ST), Vijaya Diagnostic Centre (VIJAYA.NS), GeneDx (WGS), Dian Diagnostics (300244.SZ), agilon health (AGL).
Is Personalis expensive compared with its peers?
On ev / sales it trades at 18.2× against a peer median of 2.0×, most expensive of 21 in its peer set.
How has Personalis stock performed?
Over six months to 18 Nov 2026 the shares returned +88.4% against +17.1% for the median peer; over one year +100.3%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.